Anti-TLR7 antibody [EPR2088(2)],Abcam,AB124928

Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

WB, IHC-P

Platform ID

BAB120418936

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-TLR7 antibody [EPR2088(2)]
Cat. No.AB124928
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationWB, IHC-P
ClonalityMonoclonal
Clone NumberEPR2088(2)
Concentration0.745 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Endosomal receptor that plays a key role in innate and adaptive immunity (PubMed : 14976261, PubMed : 32433612). Controls host immune response against pathogens through recognition of uridine-containing single strand RNAs (ssRNAs) of viral origin or guanosine analogs (PubMed : 12738885, PubMed : 27742543, PubMed : 31608988, PubMed : 32706371, PubMed : 35477763). Upon binding to agonists, undergoes dimerization that brings TIR domains from the two molecules into direct contact, leading to the recruitment of TIR-containing downstream adapter MYD88 through homotypic interaction (PubMed : 27742543). In turn, the Myddosome signaling complex is formed involving IRAK4, IRAK1, TRAF6, TRAF3 leading to activation of downstream transcription factors NF-kappa-B and IRF7 to induce pro-inflammatory cytokines and interferons, respectively (PubMed : 27742543, PubMed : 32706371). See full target information TLR7

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.